Aug. 4 at 12:53 PM
Busy weekend for
$XOMA. Closed on two acquisitions.
1) Acquiring
$HLVX for
$1.95 per share, plus a CVR. CVR payouts as follows:
• If HLVX clsoing cash is over
$102.95m, CVR holders will receive a pro-rata portion of the remaining cash above that.
• 90-100% of any savings from closing of HLVX's Boston office lease obligations.
• 90% of any proceeds XOMA receives in the next 5 yearw from the sale or licensing of HLVX's norovirus vaccine program. Sale or license must occur within the next two years.
Tender offer expected to close in Sept 2025.
2) Acquiring
$LVTX for between
$1.16 and
$1.24 Per Share in Cash, plus CVR. CVR payout as follows:
• 75% of the net proceeds related to LAVA’s two partnered assets
• 75% of any net proceeds from any out license or sale of LAVA’s unpartnered programs.
Tender offer expected to close in Q4 2025.
